ArticleFrontiers in oncology2025
Blood-derived ratio indexes associated with severity and prognosis of immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune checkpoint inhibitor-related cardiotoxicities (iRCs). Blood-derived inflammatory ratios may serve as practical prognostic tools for these life-threatening complications. Methods: We conducted a retrospective study of 105 iRC patients treated with ICIs between 2020 and 2023. Patients were classified by Common Terminology Criteria for Adverse Events (CTCAE) severity grades. We identified the most important blood-derived ratio indexes at iRC diagnosis associated with the severity of iRCs, 40-day major adverse cardiovascular events (MACEs), and long-term mortality using receiver operating characteristic (ROC) analyses and restricted cubic spline (RCS) curves. Kaplan-Meier survival curves, Cox regression, and subgroup analysis were also performed to evaluate them. Results: High-grade iRCs patients (n=40) showed a significantly higher system inflammation response index (SIRI) (8.21 vs. 2.21, p<0.001) and neutrophil-to-lymphocyte ratio (NLR) (11.46 vs. 5.81, p=0.001) than low-grade cases. SIRI >3.07 was strongly associated with 40-day MACEs [hazard ratios (HR)=6.56, p<0.001], whereas NLR >7.88 was associated with increased long-term mortality risk (HR = 2.33, p=0.003). Both SIRI and NLR remained significant after adjusting for cardiac biomarkers and clinical variables and were found associated with iRC severity-related cardiac biomarkers. Conclusion: SIRI and NLR are effectively associated with iRC severity and could stratify the risk of developing poor short- and long-term prognoses. These readily available inflammatory indexes could improve risk assessment and guide clinical decision-making for iRC patients. However, further prospective studies should validate their utility in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.